The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...

Migraine may be a symptom of prodromal multiple sclerosis (MS), as the risk for migraine gradually increased closer to the ...

People with multiple sclerosis (MS) face a significantly higher risk of perinatal mental illness compared to those with other ...

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

Researchers identified a key protein as a potential therapeutic target for stopping the body's immune system from mistakenly attacking itself, offering new hope for treating autoimmune diseases and ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

A new study reveals that people with multiple sclerosis (MS) experience significantly higher rates of mental illness during ...

Mothers with multiple sclerosis (MS) have an elevated incidence and prevalence of peripartum mental illness, accordi ...